公开(公告)号：US11104691B2

公开(公告)日：2021-08-31

申请号：US15507203

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Alex Kiselyov ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Daniel Clark-Frew

IPC: A61K51/00 ,  A61M36/14 ,  C07D519/00 ,  C07D471/04 ,  A61K51/04

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10765764B2

公开(公告)日：2020-09-08

申请号：US16172425

申请日：2018-10-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Thomas Martin Krulle ,  Daniel Clark-Frew ,  Duane Higgins ,  Matthew Robert Mills ,  Richard Waldron Marston ,  Samuel Coe ,  Samantha Brown ,  Sarah Hayes

IPC: A61K51/04 ,  C07D513/04 ,  C07D487/04 ,  C07D513/14 ,  C07B59/00

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20200276176A1

公开(公告)日：2020-09-03

申请号：US16799651

申请日：2020-02-24

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Jonathan Bard ,  Matthew R. Lee ,  Longbin Liu ,  Michael Edward Prime ,  Samuel Coe

IPC: A61K31/454 ,  A61K31/427 ,  A61K31/165 ,  A61K47/54

Abstract: The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

公开(公告)号：US10457675B2

公开(公告)日：2019-10-29

申请号：US16049482

申请日：2018-07-30

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Ignacio Muñoz-Sanjuán ,  Roland W. Bürli ,  Christopher A. Luckhurst ,  Daniel R. Allen ,  Gilles Raphy ,  Perla Breccia ,  Alan F. Haughan ,  Grant Wishart ,  Samantha J. Hughes ,  Rebecca E. Jarvis ,  Huw D. Vater ,  Stephen D. Penrose ,  Michael Wall ,  Andrew J. Stott ,  Elizabeth A. Saville-Stones

IPC: C07D417/04 ,  C07D231/54 ,  C07D401/04 ,  C07D403/04 ,  C07D239/70 ,  C07D239/74 ,  C07D239/88 ,  C07D277/60 ,  C07C259/08 ,  C07D231/56 ,  C07D275/04

Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use.

公开(公告)号：US10442782B2

公开(公告)日：2019-10-15

申请号：US15813001

申请日：2017-11-14

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Leonard Mitchell ,  Peter Johnson ,  Naomi Went

IPC: C07D311/20 ,  C07D307/79 ,  C07D263/58 ,  C07D235/26 ,  C07D319/18 ,  C07D317/46 ,  C07D215/18 ,  C07C62/38 ,  C07D307/94 ,  C07D309/10 ,  C07D311/58 ,  C07D317/60 ,  C07D233/64 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07C317/44 ,  C07D413/08 ,  C07D413/10 ,  C07C323/62 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07D257/04 ,  C07D203/08 ,  C07C235/82 ,  C07D207/08 ,  C07D271/07 ,  C07D207/337 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/80 ,  C07C69/757 ,  C07D203/10 ,  C07D413/12 ,  C07H15/20

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20190167821A1

公开(公告)日：2019-06-06

申请号：US16172425

申请日：2018-10-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Thomas Martin Krulle ,  Daniel Clark-Frew ,  Duane Higgins ,  Matthew Robert Mills ,  Richard Waldron Marston ,  Samuel Coe ,  Samantha Brown ,  Sarah Hayes

IPC: A61K51/04 ,  C07B59/00 ,  C07D513/04 ,  C07D487/04 ,  C07D513/14

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US10137211B2

公开(公告)日：2018-11-27

申请号：US15249223

申请日：2016-08-26

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Michael Edward Prime ,  Peter David Johnson ,  Thomas Martin Krulle ,  Daniel Clark-Frew ,  Duane Higgins ,  Matthew Robert Mills ,  Richard Waldron Marston ,  Samuel Coe ,  Samantha Brown ,  Sarah Hayes

IPC: A61K51/04 ,  C07D513/04 ,  C07D487/04 ,  C07D513/14 ,  C07B59/00

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use

公开(公告)号：US20180215745A1

公开(公告)日：2018-08-02

申请号：US15851434

申请日：2017-12-21

Applicant: CHDI Foundation, Inc.

Inventor： Leticia M. Toledo-Sherman ,  Celia Dominguez ,  Michael Prime ,  William Mitchell ,  Naomi Went

IPC: C07D413/12 ,  C07D231/56 ,  C07D215/18 ,  C07D333/06 ,  C07D241/42 ,  C07D277/24 ,  C07D277/64 ,  C07D213/46 ,  C07D307/79 ,  C07D263/56 ,  C07D261/20 ,  C07D239/74 ,  C07D237/28 ,  C07D235/08 ,  C07D217/02 ,  C07D209/08 ,  C07D407/12 ,  C07D333/28 ,  C07D333/10 ,  C07D319/18

CPC classification number: C07D413/12 ,  A61K31/343 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/428 ,  A61K31/47 ,  A61K31/502 ,  A61K31/517 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

Abstract: Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：US20170281804A1

公开(公告)日：2017-10-05

申请号：US15507214

申请日：2015-08-28

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  John Wityak ,  Jonathan Bard ,  Christopher John Brown ,  Thomas Martin Krülle ,  Daniel Clark-Frew ,  Sarah Hayes

IPC: A61K51/04 ,  C07D513/04 ,  C07D513/14 ,  C07D487/04

CPC classification number: A61K51/0455 ,  C07B2200/05 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D487/04 ,  C07D513/04 ,  C07D513/14

Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.

公开(公告)号：US20160361312A1

公开(公告)日：2016-12-15

申请号：US15042964

申请日：2016-02-12

Applicant: CHDI Foundation, Inc.

Inventor： Celia Dominguez ,  Leticia M. Toledo-Sherman ,  Stephen Martin Courtney ,  Michael Prime ,  William Mitchell ,  Christopher John Brown ,  Paula C. De Aguiar Pena ,  Peter Johnson

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/513 ,  A61K31/505

CPC classification number: A61K31/506 ,  A61K31/505 ,  A61K31/513 ,  A61K31/5377 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.